F8 and autoimmune hemolytic anemia: Two basic management strategies for patients with AHA include hemostatic therapy to control active bleeding episodes and immunosuppressive therapy to reduce further risk of bleeding by decreasing the levels of anti-FVIII autoantibody inhibitor.